Covariables | Unadjusted OR (95% CI) | Adjusted OR (95% CI) |
---|---|---|
Continuous CDAI score | 1.03 (1.01–1.04) | 1.03 (1.01–1.05) |
Age | 1.00 (0.99–1.02) | – |
Female sex | 2.16 (1.24–3.76) | 2.68 (1.33–5.39) |
Married status | 0.65 (0.41–1.03) | – |
White | 0.51 (0.21–1.25) | – |
Postgraduate education | 0.96 (0.62–1.48) | – |
High annual household income, > Can$50,000 | 0.93 (0.57–1.52) | – |
Private insurance | 1.13 (0.67–1.91) | – |
Rural residential area | 1.16 (0.66–2.06) | – |
Disease duration, yrs | 1.22 (0.79–1.89) | – |
Presence of erosions | 0.76 (0.48–1.20) | – |
ESR, mean | 1.00 (0.98–1.01) | – |
CRP, mean | 1.00 (0.99–1.01) | – |
HAQ-DI, mean | 2.05 (1.51–2.79) | 1.06 (0.63–1.76) |
HAQ pain index, mean | 1.63 (1.24–2.10) | 1.13 (0.71–1.80) |
Fatigue score, mean | 1.18 (1.10–1.28) | 1.08 (0.97–1.20) |
No. comorbidities | 1.59 (1.42–1.78) | 1.40 (1.24–1.59) |
RF-positive | 0.59 (0.37–0.92) | 0.79 (0.46–1.37) |
Prior use of csDMARD | 0.52 (0.33–0.81) | 0.55 (0.31–0.98) |
Prior use of bDMARD | 0.43 (0.19–0.98) | 0.62 (0.19–2.10) |
Current use of bDMARD | 2.38 (1.11–5.12) | 1.51 (0.53–4.29) |
Current use of csDMARD | 1.38 (0.62–3.08) | – |
Current oral glucocorticoid use | 0.88 (0.54–1.44) | – |
Oral glucocorticoid dose, mean, mg/d | 1.00 (0.96–1.04) | – |
Values in bold face are statistically significant. CDAI: Clinical Disease Activity Index; ESR: erythrocyte sedimentation rate; CRP: C-reactive protein; HAQ-DI: Health Assessment Questionnaire–Disability Index; RF: rheumatoid factor; csDMARD: conventional synthetic disease-modifying antirheumatic drug; bDMARD: biologic DMARD.